C2 Pharma, a pharmaceutical group focused on niche active pharmaceutical ingredients (APIs), has expanded its API product portfolio.   Multiple regulatory filings have been submitted to expand distribution channels globally across China, Taiwan, South Korea, Brazil, and Mexico. In addition, the company has successfully launched a Cyclopentolate Hydrochloride API in both the U.S. and European markets to position the team as a leading ophthalmic API supplier.    “Since announcing our intentions to...